ClinicalTrials.gg
RecruitingNCT05978141Updated May 20, 2026

A Registry for People With T-cell Lymphoma

An observational study in T-cell Lymphoma, NK-Cell Lymphoma and T-cell Prolymphocytic Leukemia, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 26 sites in United States. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 173 studies in Lymphoma, T-Cell with a site in United States — 34 open to participants now, 50 under way, 2 of them phase 3. Lymphoma, T-Cell · United States.

Started
2023
with 7 others
Observational
6 of 173
5 open now
Primary completion
2030-07
later than 43 of 49 live
Registered
151st of 173
by date
Lead sponsor
8 of 173
Memorial Sloan Kettering Cancer Center

Among the 173 studies in Lymphoma, T-Cell with a site in United States, this one is one of 8 that started in 2023, is one of 6 observational ones, reaches primary completion later than 43 of the 49 other live ones, and was the 151st registered.

Lymphoma, T-Cell

310 studies on the registry are indexed under Lymphoma, T-Cell; 76 are open to participants now.

Browse Lymphoma, T-Cell studies →

Open to participants now

34 of the 173 studies in Lymphoma, T-Cell with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Lymphoma, T-Cell studies recruiting now, 40 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Lymphoma, T-Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

03

Conditions studied

  • T-cell Lymphoma
  • NK-Cell Lymphoma
  • T-cell Prolymphocytic Leukemia
  • T-cell Large Granular Lymphocytic Leukemia
  • Chronic Lymphoproliferative Disorder of NK Cells
  • Aggressive NK-cell Leukemia
  • Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder)
  • Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood
  • Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form
  • Hydroa Vacciniforme-Like Lymphoproliferative Disorder
  • Adult T-cell Leukemia/Lymphoma
  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • Enteropathy-associated T-cell Lymphoma
  • Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
  • Intestinal T-Cell Lymphoma, Not Otherwise Specified
  • Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract
  • Hepatosplenic T-cell Lymphoma
  • Subcutaneous Panniculitis-Like T-Cell Lymphoma
  • Mycosis Fungoides
  • Sezary Syndrome
  • Primary Cutaneous Anaplastic Large Cell Lymphoma
  • Primary Cutaneous T-cell Lymphoma
  • Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma
  • Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Follicular T-Cell Lymphoma
  • Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
  • Anaplastic Large Cell Lymphoma, ALK-Positive
  • Anaplastic Large Cell Lymphoma, ALK-negative
  • Breast Implant-Associated Anaplastic Large Cell Lymphoma

Keywords

  • 23-190
  • T-cell lymphoma
  • Memorial Sloan Kettering Cancer Center
  • T-cell Lymphoma Master Repository
  • TCLMR
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants at Memorial Sloan Kettering Cancer Center (MSKCC) will be recruited through the Lymphoma service in the Department of Medicine and the Department of Pediatrics. Participants will be recruited at the participating centers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Adequate fresh or archival tumor or intent to obtain fresh tumor biopsy.
  • -confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):

    • T-cell prolymphocytic leukemia
    • T-cell large granular lymphocytic leukemia
    • Chronic lymphoproliferative disorder of NK cells
    • Aggressive NK-cell leukemia
    • Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
    • Chronic active EBV infection of T- and NK-cell type, systemic form
    • Hydroa vacciniforme-like lymphoproliferative disorder
    • Adult T-cell leukemia/lymphoma
    • Extranodal NK/T-cell lymphoma, nasal type
    • Enteropathy-associated T-cell lymphoma
    • Monomorphic epitheliotropic intestinal T-cell lymphoma
    • Intestinal T-cell lymphoma, not otherwise specified (NOS)
    • Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
    • Hepatosplenic T-cell lymphoma
    • Subcutaneous panniculitis-like T-cell lymphoma
    • Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
    • Sézary syndrome
    • Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
    • Primary cutaneous Gamma-Delta T-cell lymphoma
    • Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
    • Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
    • Peripheral T-cell lymphoma, not otherwise specified
    • Angioimmunoblastic T-cell lymphoma
    • Follicular T-cell lymphoma
    • Nodal peripheral T-cell lymphoma with TFH phenotype
    • Anaplastic large cell lymphoma, ALK-positive
    • Anaplastic large cell lymphoma, ALK-negative
    • Breast-implant associated anaplastic large cell lymphoma.
  • NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.

Exclusion criteria

Exclusion Criteria:

  • Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
  • Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Participants with T-Cell Lymphoma

    Participants with pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma

    Other: Optional Blood Sample and Nail Sample

Interventions

  • OtherOptional Blood Sample and Nail Sample

    Participants may provide optional research blood and nail samples for biobanking and future use

06

What researchers measure

Primary outcomes

  1. Number of participants populating the T-cell Lymphoma Master Repository/TCLMR

    To develop and populate a secure database comprised of patients with T-cell lymphomas with curated clinical characteristics and treatment outcomes matched to pathological biospecimens.

    Time frame: 10 years

07

Study locations

6 of 26 sites recruiting
  • City of Hope Cancer Center (Data collection only)
    Duarte, California 91010, United States
    Not yet recruiting
    • Jasmine Zain, MD · Contact626-359-8111
  • UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only)
    San Diego, California 92103, United States
    Not yet recruiting
    • Aaron Goodman, MD · Contact858-822-6100
  • University of California San Francisco (Data collection only)
    San Francisco, California 94143, United States
    Not yet recruiting
    • Weiyun Ai, MD · Contact415-353-2421
  • Stanford University Medical Center (Data collection only)
    Stanford, California 94305-5408, United States
    Not yet recruiting
    • Michael Khodadoust, MD · Contact650-725-5071
  • University of Colorado (Data Collection Only)
    Aurora, Colorado 80045, United States
    Not yet recruiting
    • Bradley Haverkos, MD · Contact212-639-3983
  • Yale University (Data Collection Only)
    New Haven, Connecticut 06511, United States
    Not yet recruiting
    • Francine Foss, MD · Contact203-200-4363
  • University of Miami (Data Collection Only)
    Miami, Florida 33136, United States
    Not yet recruiting
    • Jonathan Schatz, MD · Contact305-243-5302
  • Moffitt Cancer Center (Data Collection Only)
    Tampa, Florida 33612, United States
    Not yet recruiting
    • Lubomir Sokol, MD, PhD · Contact888-663-3488
  • Emory University (Data Collection Only)
    Atlanta, Georgia 30322, United States
    Not yet recruiting
    • Pamela Allen, MD, MSc · Contact404-778-0519
  • Northwestern Medicine (Data Collection)
    Chicago, Illinois 60611, United States
    Not yet recruiting
    • Jaehyuk Choi, MD, PhD · Contact312-695-8106
  • Massachusetts General Hospital (Data Collection Only)
    Boston, Massachusetts 02114, United States
    Not yet recruiting
    • Salvia Jain, MD · Contact857-392-4495
  • Dana Farber Cancer Institute (Data Collection Only)
    Boston, Massachusetts 02115, United States
    Not yet recruiting
    • Eric D Jacobsen, MD · Contact877-442-3324
  • Mayo Clinic (Data Collection Only)
    Rochester, Minnesota 55905, United States
    Not yet recruiting
    • Nora Bennani, MD · Contact507-284-2511
  • Washington University (Data Collection Only)
    St Louis, Missouri 63110, United States
    Not yet recruiting
    • Neha Mehta-Shah, MD, MSCI · Contact314-747-1171
  • University of Nebraska (Data collection only)
    Omaha, Nebraska 68198-7680, United States
    Not yet recruiting
    • Matthew Lunning, DO, FACP · Contact402-559-4000
  • Memorial Sloan Kettering at Basking Ridge (All protocol activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Steven Horwitz, MD · Contact646-608-2680
  • Memorial Sloan Kettering Monmouth (All protocol activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Steven Horwitz, MD · Contact646-608-2680
  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities)
    Commack, New York 11725, United States
    Recruiting
    • Steven Horwitz, MD · Contact646-608-2680
  • Memorial Sloan Kettering Westchester (All protocol activities)
    Harrison, New York 10604, United States
    Recruiting
    • Steven Horwitz, MD · Contact646-608-2680
  • Weill Cornell Medical Center (Data Collection Only)
    New York, New York 10021, United States
    Not yet recruiting
    • Jia Ruan, MD, PhD · Contact646-962-2064
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Steven Horwitz, MD · Contact646-608-2680
  • Memorial Sloan Kettering Nassau (All protocol activities)
    Uniondale, New York 11553, United States
    Recruiting
    • Steven Horwitz, MD · Contact646-608-2680
  • Ohio State University (Data Collection Only)
    Columbus, Ohio 43210, United States
    Not yet recruiting
    • John Reneau, MD, PhD · Contact614-293-8000
  • University of Pennsylvania (Data Collection Only)
    Philadelphia, Pennsylvania 19104, United States
    Not yet recruiting
    • Stefan Barta, MD, MS, MRCPCUK · Contact(215) 316-5151
  • Thomas Jefferson University Hospital (Data collection only)
    Philadelphia, Pennsylvania 19107, United States
    Not yet recruiting
    • Pierluigi Porcu, MD · Contact215-955-8874
  • MD Anderson Cancer Center (Data Collection Only)
    Houston, Texas 77030, United States
    Not yet recruiting
    • Swami Iyer, MD · Contact713-352-2952
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Jul 2030, 84 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Aug 7, 2023
StartActual
Jul 27, 2023
Primary completionEst.
Jul 27, 2030
CompletionEst.
Jul 27, 2030
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05978141
Responsible party
Sponsor
First posted
Aug 7, 2023
Start date
Jul 27, 2023
Primary completion
Jul 27, 2030 (estimated)
Completion
Jul 27, 2030 (estimated)
Last update
May 20, 2026

Study contacts

Steven Horwitz, MD
Contact
horwitzs@MSKCC.ORG
646-608-2680
Alison Moskowitz, MD
Contact
moskowia@mskcc.org
646-608-3726
Steven Horwitz, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion